BioCentury
ARTICLE | Financial News

Knight raises C$200M in bought deal

May 12, 2016 1:23 AM UTC

Knight Therapeutics Inc. (TSX:GUD) raised C$200 million ($154.5 million) through the sale of 25 million shares at C$8 to a syndicate of underwriters led by GMP Securities in a bought deal.

The company focuses on acquiring and in-licensing assets for the Canadian market and certain other territories. It has global rights to leishmaniasis drug Impavido miltefosine. ...